Since no relevant hits have been found in the differential expressed proteins or signaling pathways, we speculate that the changes of this intermediate protein during ciclopirox treatment may not be significant, or it may require the joint action of multiple proteins to exert its efficacy, which is a common challenge in the field of drug target identification.
← all excerpts
Ciclopirox inhibits SARS-CoV-2 replication by promoting the degradation of the nucleocapsid protein.
1
—
—